Skip to main content
ACoP 2024 Main banner
Final Program


Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Liang Zhao, PhD (he/him/his)

Professor
Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF, United States

Dr. Liang Zhao is currently a professor and director for the center of regulatory science at the School of Pharmacy, University of California San Francisco (UCSF). Prior to joining UCSF, he had served as the Director of Division of Quantitative Methods and Modeling (DQMM), Office of Research and Standards, Office of Generic Drugs, CDER/FDA between 2015 and 2024. He has demonstrated excellence and leadership in drug development and regulatory science for new and generic drugs during his 19-year professional tenure including in Pharsight as an associate consultant, BMS as a research investigator, MedImmune as an Associate Director, and FDA as Clinical Pharmacology reviewer, Pharmacometrics Team Leader, and Division Director. Dr. Zhao and his team have introduced a broad array of innovative tools in the realm of drug deliveries, bioequivalence assessment, and big data tools including machine learning to pharmacometrics. They have also implemented the Model Integrated Evidence (MIE) Industry Meeting Pilot to support regulatory communications between generic applicants and the FDA and proposed a regulatory mechanism of using Model Master File to support regulatory submissions. Liang currently serves as the Chair of the FDA ModSim WG for the Modeling & Simulation community cross FDA centers and offices. He has published over 120 peer reviewed publications and 8 book chapters. He received the 2023 Gary Neil Prize for Innovation in Drug Development from ASCPT in recognition to his contribution to clinical pharmacology and pharmacometrics.

Disclosure(s): No financial relationships to disclose

Presentation(s):

Email Liang